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A Ab bs st tr ra ac ct t
The Swedish Family-Cancer Database has been used for some 10 years in the study of familial risks at all
common sites. In the present paper we describe some of the main features of version VII of this Database,
assembled in year 2006. This update included all residents in Sweden born or immigrated in 1932 and later
(offspring) with their biological parents, a total of 11.5 million individuals. Cancer cases were retrieved from
the Swedish Cancer Registry from years 1958 to 2004, including over 1.2 million first and multiple primary
cancers and in situ tumours. We show one application of the Database in the study of familial risks in prostate
cancer, with special reference to the modification of familial risk at the time of about 50% increase in incidence
due to prostate specific antigen (PSA) screening. The familial risks for prostate cancer were 1.92 for sons of
affected fathers, 3.03 for brothers and 5.44 for men with an affected father and an affected brother. Familial
risk for prostate cancer according to the time since the first family member was diagnosed showed significant
increases for two family members being diagnosed in the same year compared to 5+ years apart. Increased
surveillance and the availability of PSA screening are the likely reasons for the overestimated familial relative
risk shortly after the first diagnosis. This lead time bias should be considered in clinical counselling.
I In nt tr ro od du uc ct ti io on n 
The family history is the prime anamnestic piece of
information in the clinical genetic counselling of many
diseases, including breast, prostate and colorectal
cancers [1, 2]. A confirmed family history of a disease
has been the initial clue about its heritable causation
and a starting point for gene identification of most
hereditary diseases. Public awareness of familial risks
and the demand for counselling have increased. In the
USA, increasing numbers of National Cancer Institute-
-designated cancer centres offer clinical genetic
counselling, not only to patients and their families but
to any concerned individuals [3]. Awareness of familial
risks and concern after diagnosis of a family member
may lead to an early diagnosis of the same disease, if
screening methods are available, as shown for
melanoma and in situ breast and cervical cancers [4].
The usefulness of the family history is critically
dependent on its accuracy. A recommendation for
mutation testing for a disease gene is usually based on
the family history, and the result may turn out to beH He er re ed diit ta ar ry y C Ca an nc ce er r iin n C Clliin niic ca all P Pr ra ac ct tiic ce e 2006; 4(4) 187
negative simply because the family history has been
wrong. Unfortunately patients tend often to be unaware
of the medical histories of their relatives. Recently, data
on the accuracy of family histories have been
accumulated by comparing reported histories to those
with medical documentation. Murff et al. collected
literature on the accuracy of family history data for
cancer [5]. The positive predictive value (positives of
true positives) of the reported family history compared
to medical diagnosis in a first-degree relative was 93%
for breast, 85% for prostate, 81% for colon, 69% for
ovarian and 37% for endometrial cancers when
reported by cancer patients. When the family histories
were reported by healthy controls, the positive predictive
values were about 20 percent units lower; the worst
were ovarian (25%) and endometrial cancers (17%).
The percentages were lower for the second-degree
relatives than for the first-degree relatives. Many of the
findings were similar in a Swedish study, which
suggested that reporting is worse for rare cancers;
somewhat surprisingly, the accuracy of reporting cancer
in siblings was worse than that in parents [6]. These
data are worrisome as they are, but they may be even
worse for many other diseases, for which the
diagnostics have not been as uniform as they have
been for cancer during the past half century.
Familial clustering of cancer can be identified
through a number of approaches. The clinical
identification of probands and construction of pedigrees
has been the classical approach to heritable diseases.
A unique population screening program for familial
cancer has been carried out among the 1.5 million
inhabitants of the West Pomeranian Region around
Szczecin in Poland [7, 8]. As a further alternative,
population-based datasets on familial cancer have
been used in Utah, Iceland, UK, Denmark, Finland and
Sweden [9-13]. The largest dataset on familial cancer
is the Swedish Family-Cancer Database, which has
been updated periodically, and in the present article
we report the seventh update, covering cancers up to
year 2004, abbreviated FCD2004. We show an
application of the Database to prostate cancer, with
special reference to the familial risks during a period
of increasing incidence.
T Th he e F Fa am mi il ly y- -C Ca an nc ce er r D Da at ta ab ba as se e o of f y ye ea ar r 2 20 00 04 4
Statistics Sweden created a family database, the
“Second Generation Register”, in 1995 [14]. After 
a few expansions, it covered offspring born after 1931
with their parents, renamed as the “Multigeneration
Register” to indicate that the number of generations
was more than two. We have linked this Register to the
Swedish Cancer Registry (1958-2004) to make the
Family-Cancer Database (MigMed2) in year 2006 for
the seventh time, called here FCD2004 [15, 16]. For
the first time, FCD2004 contains data on all
immigrants, whereas the previous versions only
included those who had had children in Sweden. In
FCD all data are organized in child-mother-father
triplets; the parents have been registered at the time of
birth of the child, allowing tracking of “biological”
parents in spite of divorce and remarriage. 
FCD2004 identified a total of 11.5 million persons,
divided into parental and offspring generations. An
overwhelming proportion (97.9%) of offspring born in
Sweden have information on parents, but the
proportion is much smaller for offspring born outside
Sweden, for obvious reasons (Table 1). Even for those
born in Sweden, the parental links are more numerous
for living than for deceased individuals; 10.9% of
offspring with cancer lack parental links. FCD2004
contains 1.2 million tumour notifications, compared
to 1.1 million in FCD2002 (Table 2); among tumours
in FCD2004, 796,000 are first primary cancers,
85,000 are multiple primaries and 237,000 are in situ
cancers, dominated by cervical in situ cancers. The
annual accumulation of cancer cases to the parental
and offspring generation in FCD2004 and FCD2002
is shown in Fig. 1. The offspring generation had initially
far fewer cases than the parental one but now in
FCD2004 the number of cases among the offspring &
parent group (i.e. those who were first offspring and
then became parents) exceeded the case numbers of
the parental generation. The parental cases are
decreasing in the course of time because the parental
generation was born before year 1932 and it is dying
away. The ‘All’ curve is the sum of the three other
mutually exclusive curves. 
A An n a ap pp pl li ic ca at ti io on n o of f t th he e D Da at ta ab ba as se e: : 
p pr ro os st ta at te e c ca an nc ce er r
According to the Cancer Incidence in Five
Continents, the difference in incidence of prostate
cancer between the highest (202/100,000 for Detroit
African Americans) and the lowest (1.1 for Qidong,
China) rates is larger than for any major cancer [17].
The reasons for the difference are not understood but
one is the ever rising incidence in the affluent countries.
The increase in incidence, 3.4-fold in Sweden, is shown
in Fig. 2 for the period 1960-2004, based on the
Swedish Cancer Registry. There seem to be two different
patterns in the age-incidence relationships. The first
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T Ta ab bl le e 1 1. . Number of individuals in the offspring generations in FCD2004 according to country of birth
N Nu um mb be er r o of f o of ff fs sp pr ri in ng g i in n F FC CD D2 20 00 04 4
T To ot ta al l n no o. .      O Of ff fs sp pr ri in ng g  O Of ff fs sp pr ri in ng g l li in nk ke ed d                 O Of ff fs sp pr ri in ng g w wi it th h c ca an nc ce er r 
o of f o of ff fs sp pr ri in ng g w wi it th h c ca an nc ce er r t to o p pa ar re en nt t n no ot t l li in nk ke ed d t to o p pa ar re en nt t
n n n n [ [% %] ] n n [ [% %] ] n n [ [% %] ]
All offspring 8 965 636 304 083 3.4 7 783 176 86.8 59 569 0.7
Living offspring 8 633 969 195 631 2.3 7 552 456 87.5 28 766 0.3
Deceased offspring 331 667 108 452 32.7 230 720 69.6 30 803 9.3
N Nu um mb be er r o of f o of ff fs sp pr ri in ng g i in n F FC CD D2 20 00 02 2
T To ot ta al l n no o. .      O Of ff fs sp pr ri in ng g  O Of ff fs sp pr ri in ng g l li in nk ke ed d                 O Of ff fs sp pr ri in ng g w wi it th h c ca an nc ce er r 
o of f o of ff fs sp pr ri in ng g w wi it th h c ca an nc ce er r t to o p pa ar re en nt t n no ot t l li in nk ke ed d t to o p pa ar re en nt t
n n n n [ [% %] ] n n [ [% %] ] n n [ [% %] ]
All 7 400 436 224 225 3.0 7 240 222 97.8 26 254 0.4
Living offspring  7 110 978 144 602 2.0 7 010 092 98.6 8 936 0.1
Deceased offspring 289 458 79 623 27.5 230 130 79.5 17 318 6.0
N Nu um mb be er r o of f S Sw we ed di is sh h- -b bo or rn n o of ff fs sp pr ri in ng g i in n F FC CD D2 20 00 04 4
T To ot ta al l n no o. .      O Of ff fs sp pr ri in ng g  O Of ff fs sp pr ri in ng g l li in nk ke ed d                 O Of ff fs sp pr ri in ng g w wi it th h c ca an nc ce er r 
o of f o of ff fs sp pr ri in ng g w wi it th h c ca an nc ce er r t to o p pa ar re en nt t n no ot t l li in nk ke ed d t to o p pa ar re en nt t
n n n n [ [% %] ] n n [ [% %] ] n n [ [% %] ]
All offspring 7 537 563 268 007 3.6 7 376 394 97.9 29 280 0.4
Living offspring 7 249 706 173 097 2.4 7 152 845 98.7 10 207 0.1
Deceased offspring 287 857 94 910 33.0 223 549 77.7 19 073 6.6
N Nu um mb be er r o of f f fo or re ei ig gn n- -b bo or rn n o of ff fs sp pr ri in ng g i in n F FC CD D2 20 00 04 4
T To ot ta al l n no o. .      O Of ff fs sp pr ri in ng g  O Of ff fs sp pr ri in ng g l li in nk ke ed d                 O Of ff fs sp pr ri in ng g w wi it th h c ca an nc ce er r 
o of f o of ff fs sp pr ri in ng g w wi it th h c ca an nc ce er r t to o p pa ar re en nt t n no ot t l li in nk ke ed d t to o p pa ar re en nt t
n n n n [ [% %] ] n n [ [% %] ] n n [ [% %] ]
All offspring 1 402 042 35 995 2.6 400 544 28.6 30 217 2.2
Living offspring 1 358 869 22 513 1.7 393 432 29.0 18 543 1.4
Deceased offspring 43 173 13 482 31.2 7 112 16.5 11 674 27.0
N Nu um mb be er r o of f o of ff fs sp pr ri in ng g w wi it th h u un nk kn no ow wn n b bi ir rt th h c co ou un nt tr ry y i in n F FC CD D2 20 00 04 4
T To ot ta al l n no o. .      O Of ff fs sp pr ri in ng g  O Of ff fs sp pr ri in ng g l li in nk ke ed d                 O Of ff fs sp pr ri in ng g w wi it th h c ca an nc ce er r 
o of f o of ff fs sp pr ri in ng g w wi it th h c ca an nc ce er r t to o p pa ar re en nt t n no ot t l li in nk ke ed d t to o p pa ar re en nt t
n n n n [ [% %] ] n n [ [% %] ] n n [ [% %] ]
All offspring 26 031 81 0.3 6 238 24.0 72 0.3
Living offspring 25 394 21 0.1 6 179 24.3 16 0.1
Deceased offspring 637 60 9.4 59 9.3 56 8.8H He er re ed diit ta ar ry y C Ca an nc ce er r iin n C Clliin niic ca all P Pr ra ac ct tiic ce e 2006; 4(4) 189
The updated Swedish family-cancer database used to assess familial risks of prostate cancer during rapidly increasing incidence
T Ta ab bl le e 2 2. . Number of cancers in the FCD2004 compared to FCD2002
N Nu um mb be er r o of f c ca an nc ce er r n no ot ti if fi ic ca at ti io on ns s f fo or r f fi ir rs st t a an nd d m mu ul lt ti ip pl le e p pr ri im ma ar ry y i in nv va as si iv ve e a an nd d i in n s si it tu u c ca an nc ce er rs s i in n F FC CD D2 20 00 04 4, , 1 19 95 58 8- -2 20 00 04 4
F Fi ir rs st t p pr ri im ma ar ry y M Mu ul lt ti ip pl le e p pr ri im ma ar ry y I In n s si it tu u A Al ll l
Father 326 543 40 924 32 385 399 852
Mother 274 372 36 292 58 240 368 904
Father/son 93 261 6 053 10 292 109 606
Mother/daughter 128 479 10 872 136 516 275 867
Son 31 734 1 644 2 493 35 871
Daughter 29 694 2 346 22 492 54 532
All 884 083 98 131 262 418 1 244 632
N Nu um mb be er r o of f c ca an nc ce er r n no ot ti if fi ic ca at ti io on ns s f fo or r f fi ir rs st t a an nd d m mu ul lt ti ip pl le e p pr ri im ma ar ry y i in nv va as si iv ve e a an nd d i in n s si it tu u c ca an nc ce er rs s i in n F FC CD D2 20 00 02 2, , 1 19 95 58 8- -2 20 00 02 2
F Fi ir rs st t p pr ri im ma ar ry y M Mu ul lt ti ip pl le e p pr ri im ma ar ry y I In n s si it tu u A Al ll l
Father 315 921 37 379 30 057 383 357
Mother 270 039 33 676 64 203 367 918
Father/son 65 269 3 832 6 982 76 083
Mother/daughter 97 442 7 658 114 976 220 076
Son 24 230 1 105 1 752 27 087
Daughter 23 075 1 614 18 671 43 360
All 795 976 85 264 236 641 1 117 881
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F Fi ig g. . 1 1. . 
one prevailed until about year 1995, and it was
characterized by a preferential increase in incidence
in those older than 70 years [18]. This increase
coincided with a more common and intense
application of prostatic biopsies and transurethral
resection techniques [19]. In the second phase, after
year 1997, the 50% increase extended preferentially
to younger age groups and it coincided with a wideH He er re ed diit ta ar ry y C Ca an nc ce er r iin n C Clliin niic ca all P Pr ra ac ct tiic ce e 2006; 4(4) 190
application of opportunistic prostate specific antigen
(PSA) testing [20, 21]. The widespread use of PSA
testing was the probable cause of the upward shift in
incidence between years 1998 and 2004.
The familial risks for prostate cancer are shown in
Table 3 based on FCD2004 (oldest age for offspring
72 years) and FCD2002 (oldest age for offspring 70
years). The methods, based on standardized incidence
ratio (SIR) and 95% confidence intervals (CIs), have been
described elsewhere [15, 16]. The number of affected
father-son pairs has increased from 1501 to 2546 and
that of affected brother pairs from 361 to 898; for three
affected individuals/family the number has increased
from 118 to 259. The increases in familial cases show
the reason why the biannual updating of FCD are
considered worthwhile. All the familial risks have
decreased slightly because of the aging population; in
FCD2004 they were 1.92 for sons of affected fathers,
3.03 for brothers and 5.44 for men with an affected
father and an affected brother (Table 3).
With increasing incidence and access, changes in
familial risks are expected; some evidence has been
seen for prostate and some other cancers earlier 
[4, 18, 22]. The methods, based on Poisson regression
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males
1960        1965         1970        1975        1980         1985        1990         1995        2000
y ye ea ar r o of f d di ia ag gn no os si is s
P Pe er r 1 10 00 0 0 00 00 0
F Fi ig g. . 2 2. . Prostate cancer incidence in Sweden, based on the Swedish
Cancer Registry
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T Ta ab bl le e 3 3. . SIR
1) for invasive prostate cancer in men by family history
F FC CD D2 20 00 04 4 F FC CD D2 20 00 02 2
F Fa am mi il ly y h hi is st to or ry y O O E E S SI IR R 9 95 5% % C CI I O O E E S SI IR R 9 95 5% % C CI I
Father only 2 546 1 324 1 1. .9 92 2 1.85 2.00 1 501 767 1 1. .9 96 6 1.86 2.06
Brother only 898 296 3 3. .0 03 3 2.00 4.57 361 107 3 3. .3 37 7 2.14 5.29
Father & brother 259 48 5 5. .4 44 4 3.39 8.68 118 18 6 6. .6 60 0 3.86 11.18
No history 14 473 16 516 0.88 0.86 0.89 8 573 9 662 0.89 0.87 0.91
All brothers (ref) 9 738 9 738 1 0.69 1.44 5 490 5 490 1 0.69 1.45
All (ref) 18 176 18 176 1 0.99 1.01 10 553 10 553 1 0.98 1.02
Period of follow-up: 1961-2004 Period of follow-up: 1961-2002
1) SIR standardized by age, calender period, socioeconomic status and residential region
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F Fi ig g. . 3 3. . Dependence of familial risk for prostate cancer in sons on
the time after father’s diagnosis of prostate cancer (95%CIs and
number of father-son pairs is shown inside the bars)
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F Fi ig g. . 4 4. . Dependence of familial risk for prostate cancer in brothers
on the time after the first brother’s diagnosis of prostate cancer
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analysis, have been described elsewhere [4]; relative
risk (RR), its 95%CIs and a two-sided p-value were
calculated. We assessed familial risk for prostate cancer
in father-son pairs using FCD2004 and FCD2002
according to the time since the first family member was
diagnosed (Fig. 3). The risk was highest for sons to be
diagnosed with prostate cancer in the year of the
father’s diagnosis, and higher in FCD2004 (RR 3.37,
N=31, 95%CI 2.34-4.86) than in FCD2002 (2.72).
In FCD2004 the difference between the same year and
the reference, 5+ years (RR 2.10, N=2504, 95%CIs
2.01-2.19), was significant, p=0.011. The similar
analysis for brothers showed a somewhat different
result, as the RRs were systematically lower for
FCD2004 than FCD2002 (Fig. 4); however, the
difference between the same and 5+ years remained.
In FCD2004 the RR for diagnosis of both brothers in
the same year was 5.06 (N=101, 95%CIs 3.86-6.64)
compared to 3.30 (N=134, 95%CIs 2.60-4.18) in
5+ years, p=0.019.
C Co on nc cl lu us si io on ns s
The median age at diagnosis of cancer at all sites
is about 70 years in Sweden [23]. Thus the offspring
population aged up to 72 years in FCD2004 has
passed the median age. If familial cancers indeed are
diagnosed at a younger age than sporadic cancers,
as they are for known hereditary cancer syndromes,
then we can expect to have captured a large
proportion of familial cancers, particularly for relatively
early onsets cancers, such as breast cancer. However,
for relatively late onset cancers, exemplified by prostate
cancer here, larger numbers of familial cases are
obtained by extending the data to older individuals.
Data from the Utah population database suggest that
familial cancers can be detected even at old ages [10].
Even hereditary cancers can be found at late age;
when mutation screening for hereditary nonpolyposis
colorectal cancer (HNPCC) was extended to older
patients, mutation-positive individuals were detected
with a median age of 61 years, compared to the long-
held median age of 44 years [24]. Whether familial
cancers tend to be of early onset is yet to be seen and
the future updates of FCD will resolve the issue. 
The successes in early diagnosis and management
of heritable cancers have shown that inherited cancers
are no longer inevitable. Although genetic testing has
become an important method for at-risk families of
certain cancers, it covers a small proportion of all
familial cancers. Empirical risk estimates from
epidemiological studies have proven to be useful for
familial breast and prostate cancers, and it is
recommended that reliable risk estimates for other
cancers also be seriously considered for routine clinical
recommendations [25]. A familial low-penetrant risk
in a common cancer may result in more cases in 
a given population than a high risk of a rare cancer.
Furthermore, familial risks are higher for some relatively
rare neoplasms, causing hardship in the affected
families. Epidemiological results on familial risk are
sometimes dismissed because ‘they cannot be
translated into individual risks’. However, there are
many examples on everyday use of epidemiological
data in clinical risk estimation [16, 25]. In the absence
of known genes, reliable individual risk estimates need
to be generated among populations. 
Increased surveillance and the availability of
screening methods may result in overestimated familial
relative risks shortly after the first diagnosis. We show
here increased risks for prostate cancer both for father-
son pairs and for brothers in the year of the first family
member’s diagnosis. The findings are consistent with
data from FCD2002 [4, 18, 22]. However, even
though the overall effect of this bias on familial risks
is small, it calls for consideration in clinical counselling
of individuals from families in which synchronous
cancers were diagnosed. The lead time bias should
not misguide the doctor, who should instead explain
the possibility of bias to the patients and their family
members in order to comfort their anxiety. 
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